Literature DB >> 32606115

Filgrastim induced thrombocytopenia.

Ghazal Kango1, Faysal Haroun2.   

Abstract

Drug-induced thrombocytopenia (DITP) is suggested by severe thrombocytopenia with subsequent recovery of platelet count after removal of the offending drug. The diagnosis is ascertained when there is reproducibility of thrombocytopenia with repeated exposure. Filgrastim is used during peripheral blood progenitor cell harvest during autologous stem cell transplantation in the setting of multiple myeloma to prolong event-free survival and overall mortality. The following case illustrates all of the suggestive features of DITP after filgrastim exposure during elective stem cell harvest. Due to the inability to tolerate filgrastim, autologous stem cell transplant was aborted in this patient and he was maintained on induction chemotherapy. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Haematology (incl blood transfusion); cancer - see oncology; haematology (drugs and medicines); malignant and benign haematology; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2020        PMID: 32606115      PMCID: PMC7328747          DOI: 10.1136/bcr-2020-234584

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

Review 1.  Molecular mechanisms of drug-induced thrombocytopenia.

Authors:  J K Burgess
Journal:  Curr Opin Hematol       Date:  2001-09       Impact factor: 3.284

2.  Profound thrombocytopenia related to G-CSF.

Authors:  Jason C Kovacic; Peter Macdonald; Judith Freund; John E J Rasko; Roger Allan; Vivian B Fernandes; David Ma; John Moore; Robert M Graham
Journal:  Am J Hematol       Date:  2007-03       Impact factor: 10.047

3.  Drug-induced thrombocytopenia: MIBS trumps LIBS.

Authors:  Beng H Chong
Journal:  Blood       Date:  2012-06-28       Impact factor: 22.113

4.  G-CSF-induced thrombocytopenia in a healthy donor.

Authors:  O Minelli; F Falzetti; M Di Ianni; M Onorato; S Plebani; C Silvani; A Tabilio
Journal:  Bone Marrow Transplant       Date:  2008-09-29       Impact factor: 5.483

5.  The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia.

Authors:  T Wun
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

6.  Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.

Authors:  Li Young Ahn; Kwang-Hee Shin; Kyoung Soo Lim; Tae-Eun Kim; Hyewon Jeon; Seo Hyun Yoon; Joo-Youn Cho; Sang-Goo Shin; In-Jin Jang; Kyung-Sang Yu
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

7.  Granulocyte colony stimulating factor in neonatal alloimmune neutropenia: a possible association with induced thrombocytopenia.

Authors:  Christina Wiedl; Andrew W Walter
Journal:  Pediatr Blood Cancer       Date:  2010-07-01       Impact factor: 3.167

8.  Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry.

Authors:  Javier de la Rubia; Felipe de Arriba; Cristina Arbona; María J Pascual; Concha Zamora; Andrés Insunza; Dorleta Martínez; Carmen Paniagua; Miguel A Díaz; Miguel A Sanz
Journal:  Haematologica       Date:  2008-04-02       Impact factor: 9.941

9.  Drug-induced thrombocytopenia during G-CSF therapy in a patient with chronic neutropenia.

Authors:  Namık Özbek; Emel Özyürek
Journal:  Turk J Haematol       Date:  2006-03-05       Impact factor: 1.831

10.  Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors.

Authors:  T A Lane; A D Ho; A Bashey; S Peterson; D Young; P Law
Journal:  Transfusion       Date:  1999-01       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.